Novo Nordisk Oral Wegovy Pill Sees Strong Early Adoption in the United States
Novo Nordisk's oral Wegovy pill reached over 18,000 prescriptions in its first full week after a January launch. The early data indicates strong market demand.
Insights:
Novo Nordisk A/S officially launched its oral Wegovy pill in the US 
USon January 5, 2026, and the medication has already demonstrated significant early market uptake. According to data provided by IQVIA, the drug recorded 18,410 prescriptions in its first full week of availability. This robust performance followed an initial four-day period after the launch during which the pill received 3,071 prescriptions, indicating a rapid acceleration in patient and provider demand for the new treatment option.
USon January 5, 2026, and the medication has already demonstrated significant early market uptake. According to data provided by IQVIA, the drug recorded 18,410 prescriptions in its first full week of availability. This robust performance followed an initial four-day period after the launch during which the pill received 3,071 prescriptions, indicating a rapid acceleration in patient and provider demand for the new treatment option.Analysts cited by Reuters have observed that this prescription rate is currently tracking ahead of other notable GLP-1 drug launches. James Gordon, an analyst at Barclays, characterized the early data for the oral Wegovy launch as very strong. This momentum comes as the obesity treatment market has become significantly better established than it was during the introduction of earlier injectable medications, providing a more receptive environment for needle-free alternatives.
